Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
DTC has a generally favorable prognosis. The possibility to discriminate between patients with aggressive tumors and those with a more indolent behavior may reduce the need for unnecessary treatments. Aim of this observational study is to evaluate how anamnestic, clinical, and histopathological variables may influence the outcome of the enrolled patients, both regarding morbidity and mortality and in terms of therapeutic choices. The study aims to evaluate the prognostic impact of the therapeutic interventions in terms of efficacy and regarding the appearance of adverse events.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Dynamic risk stratification | impact of the different variables on the DRS | one year from the primary treatment |
| Dynamic risk stratification | impact of the different variables on the DRS | five years from the primary treatment |
| Dynamic risk stratification | impact of the different variables on the DRS | ten years from the primary treatment |
| Progression-free survival | impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer | one year from the primary treatment |
| Progression-free survival | impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer | five years from the primary treatment |
| Progression-free survival | impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer | ten years from the primary treatment |
| Overall survival | impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer | one year from the primary treatment |
| Overall survival |
Not provided
Not provided
Inclusion Criteria:
- thyroid cancer diagnosis
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
all consecutive patients referred to our tertiary clinical center for thyroid cancer
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Laura Fugazzola, MD | Contact | +390261911 | 2727 | l.fugazzola@auxologico.it |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Istituto Auxologico Italiano, IRCCS | Recruiting | Milan | 20149 | Italy |
Not provided
| ID | Term |
|---|---|
| D013964 | Thyroid Neoplasms |
| ID | Term |
|---|---|
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D006258 | Head and Neck Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer |
| five years from the primary treatment |
| Overall survival | impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer | ten years from the primary treatment |
| D004700 |
| Endocrine System Diseases |
| D013959 | Thyroid Diseases |